Table 2.
Use of reperfusion therapy, heparin, and oral anticoagulants in the acute management of ACS according to estimated CrC
| Medication Use | ≤45 ml/min (n = 152) | 45 to 60 ml/min (n = 198) | >60 ml/min (n = 728) | Differencea,c |
|---|---|---|---|---|
| Thrombolysis or primary PTCR in candidates by ECG criteriab (%) | 22 (69) | 52 (83) | 182 (77) | −8 (−24, 8) |
| tertiary care centers | 16 (84) | 41 (85) | 142 (80) | 4 (−13, 21) |
| community-based centers | 6 (46) | 11 (73) | 40 (68) | −22 (−52, 8) |
| Heparin use—acute treatment of ACS (%) | 138 (91) | 171 (86) | 663 (91) | 0 (−5, 5) |
| Heparin use or already receiving warfarin—acute treatment of ACS (%) | 143 (94) | 172 (87) | 664 (91) | 3 (−1, 7) |
a
Reported differences are between subjects with a CrC ≤45 ml/min and the reference group (>60 ml/min) and are expressed in percent with a 95% CI.
b
There were 330 subjects considered appropriate candidates for reperfusion therapy by ECG criteria (≥1-mm ST-segment elevation in two leads): 32 with a CrC ≤45 ml/min, 63 in the 45- to 60-ml/min category, and 235 with a CrC >60 ml/min.
c
There were no significant between-group differences by χ2.